文献速递甲状腺疾病

甲状腺低分化癌:现状与未来展望

Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects.
PubMed 文献 · Thyroid · 2019-01-01

甲状腺低分化癌(PDTC)是罕见但临床意义重大的非间变性滤泡细胞来源甲状腺癌,多数此类癌的死亡由其导致。本文综述了PDTC的诊断标准、临床病理特征、管理、结局及下一代测序研究报道的基因组驱动因素,并讨论了改善患者结局的未来前景。

要点

  • PDTC患者常表现为高龄、男性、晚期局部病变和远处转移等不良特征。
  • 手术清除所有大体病变可实现满意的局部控制,但多数患者死于远处转移。
  • BRAFV600E或RAS突变(分别27%和24%)是互斥的主要驱动因素,TERT启动子突变最常见(40%)。

核心结论

  • 对PDTC临床病理和分子特征的新认识,结合超深度测序技术的进步,有助于聚焦开发新型靶向疗法并改善患者结局。

研究设计与样本

  • 综述,基于近期下一代测序研究汇总PDTC的诊断标准、临床病理特征、管理、结局及基因组驱动因素。

主要发现

  • PDTC患者5年疾病特异性生存率报告为66%。
  • 多变量分析中,不良生存预测因素包括年龄>45岁、T4a病理分期、甲状腺外侵犯、高核分裂率、肿瘤坏死和就诊时远处转移。
  • BRAFV600E或RAS突变分别占27%和24%,TERT启动子突变占40%,EIF1AX突变占11%,TP53突变占16%。
  • 致命性PDTC中MED12和RBM10新突变率分别为15%和12%。
  • 染色体1q获得是PDTC最常见的臂水平改变,且患者生存率更差;染色体22q缺失与RAS突变强相关。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Poorly differentiated thyroid cancer (PDTC) is a rare but clinically highly significant entity because it accounts for most fatalities from non-anaplastic follicular cell-derived thyroid cancer. Due to the relative rarity of the disease and heterogeneous diagnostic criteria, studies on PDTC have been limited. In light of the evolution of ultra-deep next-generation sequencing technologies and through correlation of clinicopathologic and genomic characteristics of PDTC, an improved understanding of the biology of PDTC has been facilitated. Here, the diagnostic criteria, clinicopathologic characteristics, management, and outcomes in PDTC, as well as genomic drivers in PDTC reported in recent next-generation sequencing studies, are reviewed. In addition, future prospects in improving the outcomes in PDTC patients are reviewed. SUMMARY: PDTC patients tend to present with adverse clinicopathologic characteristics: older age, male predominance, advanced locoregional disease, and distant metastases. Surgery with clearance of all gross disease can achieve satisfactory locoregional control. However, the majority of PDTC patients die of distant disease. Five-year disease-specific survival for PDTC patients has been reported at 66%. On multivariate analysis, reported predictors of poor survival in PDTC patients have been older age (>45 years), T4a pathological stage, extrathyroidal extension, high mitotic rate, tumor necrosis, and distant metastasis at presentation. BRAFV600E or RAS mutations (27% and 24% of cases, respectively) remain mutually exclusive main drivers in PDTC. TERT promoter mutations represent the most common alteration in PDTC (40%). Mutation in translation initiation factor EIF1AX (11%) and tumor suppressor TP53 (16%) have also been reported in PDTC. High rates of novel mutations (MED12 and RBM10) have been reported in fatal PDTC (15% and 12%, respectively). Chromosome 1q gains represent the most common arm-level alterations in PDTC, and those patients show worse survival rates. Chromosome 22q losses are also found in PDTC and show strong association with RAS mutation. CONCLUSIONS: These new insights into the clinicopathologic and molecular characteristics of PDTC, together with further advancement in ultra-deep sequencing technologies, will be conducive in narrowing the focus in order to develop novel targeted therapies and improve the outcomes in PDTC patients.

来源:Thyroid,查看原文。版权归原作者所有。

引用

  1. Ibrahimpasic T, Ghossein R, Shah JP, et al. Poorly Differentiated Carcinoma of the Thyroid Gland: Current Status and Future Prospects. Thyroid. 2019. PMID: 30747050. doi:10.1089/thy.2018.0509

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。